» Articles » PMID: 24813206

RNA and Imidazoquinolines Are Sensed by Distinct TLR7/8 Ectodomain Sites Resulting in Functionally Disparate Signaling Events

Abstract

TLRs 7 and 8 are pattern recognition receptors controlling antiviral host defense or autoimmune diseases. Apart from foreign and host RNA, synthetic RNA oligoribonucleotides (ORN) or small molecules of the imidazoquinoline family activate TLR7 and 8 and are being developed as therapeutic agonists. The structure-function relationships for RNA ORN and imidazoquinoline sensing and consequent downstream signaling by human TLR7 and TLR8 are unknown. Proteome- and genome-wide analyses in primary human monocyte-derived dendritic cells here showed that TLR8 sensing of RNA ORN versus imidazoquinoline translates to ligand-specific differential phosphorylation and transcriptional events. In addition, TLR7 and 8 ectodomains were found to discriminate between RNA ORN and imidazoquinolines by overlapping and nonoverlapping recognition sites to which murine loss-of-function mutations and human naturally occurring hyporesponsive polymorphisms map. Our data suggest TLR7 and TLR8 can signal in two different "modes" depending on the class of ligand. Considering RNA ORN and imidazoquinolines have been regarded as functionally interchangeable, our study highlights important functional incongruities whose understanding will be important for developing TLR7 or 8 therapeutics with desirable effector and safety profiles for in vivo application.

Citing Articles

naRNA-LL37 composite DAMPs define sterile NETs as self-propagating drivers of inflammation.

Bork F, Greve C, Youn C, Chen S, Leal V, Wang Y EMBO Rep. 2024; 25(7):2914-2949.

PMID: 38783164 PMC: 11239898. DOI: 10.1038/s44319-024-00150-5.


Study of the Synergistic Immunomodulatory and Antifibrotic Effects of Dual-Loaded Budesonide and Serpine1 siRNA Lipid-Polymer Nanoparticles Targeting Macrophage Dysregulation in Tendinopathy.

Lopez-Cerda S, Molinaro G, Pareja Tello R, Correia A, Kunig S, Steinberger P ACS Appl Mater Interfaces. 2024; 16(15):18643-18657.

PMID: 38564504 PMC: 11040533. DOI: 10.1021/acsami.4c02363.


Loss of the Immunomodulatory Transcription Factor BATF2 in Humans Is Associated with a Neurological Phenotype.

Zsurka G, Appel M, Nastaly M, Hallmann K, Hansen N, Nass D Cells. 2023; 12(2).

PMID: 36672163 PMC: 9856319. DOI: 10.3390/cells12020227.


The subversion of toll-like receptor signaling by bacterial and viral proteases during the development of infectious diseases.

Ciaston I, Dobosz E, Potempa J, Koziel J Mol Aspects Med. 2022; 88:101143.

PMID: 36152458 PMC: 9924004. DOI: 10.1016/j.mam.2022.101143.


Nanocarriers for effective delivery: modulation of innate immunity for the management of infections and the associated complications.

Ko C, Zang S, Zhou Y, Zhong Z, Yang C J Nanobiotechnology. 2022; 20(1):380.

PMID: 35986268 PMC: 9388998. DOI: 10.1186/s12951-022-01582-8.


References
1.
Gay N, Gangloff M, ONeill L . What the Myddosome structure tells us about the initiation of innate immunity. Trends Immunol. 2011; 32(3):104-9. DOI: 10.1016/j.it.2010.12.005. View

2.
Panter G, Kuznik A, Jerala R . Therapeutic applications of nucleic acids as ligands for Toll-like receptors. Curr Opin Mol Ther. 2009; 11(2):133-45. View

3.
von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku C . Pyogenic bacterial infections in humans with MyD88 deficiency. Science. 2008; 321(5889):691-6. PMC: 2688396. DOI: 10.1126/science.1158298. View

4.
Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R . Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011; 186(8):4794-804. DOI: 10.4049/jimmunol.1000702. View

5.
Peter M, Kubarenko A, Weber A, Dalpke A . Identification of an N-terminal recognition site in TLR9 that contributes to CpG-DNA-mediated receptor activation. J Immunol. 2009; 182(12):7690-7. DOI: 10.4049/jimmunol.0900819. View